Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ofloxacin + roxithromycin is a fixed-dose combination of two antibacterial agents used to treat a variety of bacterial infections. Ofloxacin is a synthetic fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, thereby preventing DNA replication and leading to cell death. Roxithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit, inhibiting protein synthesis in susceptible bacteria. The combination may be used for respiratory tract infections, skin and soft tissue infections, genitourinary tract infections, and other conditions where both Gram-positive and Gram-negative coverage is desired. In vitro studies suggest potential additive or synergistic effects against certain pathogens when these drugs are combined[1][3]. Both agents are orally bioavailable small molecules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ofloxacin + roxithromycin.